-transparent.png){kind=logo}
Pure, E. coli-derived recombinant murine interleukin 1 alpha (IL 1 alpha) was labeled with 125I and used for receptor binding studies. The 125I-IL 1 binds to murine EL-4 thymoma cells in a specific and saturable manner. Scatchard plot analysis for binding studies carried out at 4 degrees C reveals a single type of high affinity binding site with an apparent dissociation constant of approximately 2.6 X 10(-10) M and the presence of approximately 1200 binding sites per cell. The rate of association of the 125I-IL 1 with EL-4 cells is slow, requiring more than 3 h to reach apparent steady state at 4 degrees C. Cell-bound 125I-IL 1 cannot be dissociated from EL-4 cells upon removal of unbound 125I-IL 1 and incubation of the cells at 4 degrees C in the presence or absence of unlabeled IL 1. Unlabeled recombinant murine IL 1 competes for 125I-IL 1 binding in a dose-dependent manner, whereas interferon-alpha A, interleukin 2 (IL 2), epidermal growth factor, and nerve growth factor have no effect. The 125I-IL 1 binding site is sensitive to trypsin, suggesting that it is localized on the cell surface. We have also examined the ability of purified recombinant human IL 1 alpha and IL 1 beta to compete for binding of the radiolabeled murine IL 1 to its receptor and to stimulate IL 2 production by EL-4 cells. Previous reports have shown that human IL 1 alpha is approximately 60% homologous in amino acid sequence with murine IL 1, but that human IL 1 beta is only about 25% homologous with either murine IL 1 or human IL 1 alpha. Despite these marked differences, however, we report here that both human IL 1 proteins are able to recognize the same binding site as mouse IL 1. In addition, murine as well as both human IL 1 proteins stimulate IL 2 production by EL-4 cells.
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
November 1992,
European journal of immunology,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
August 1992,
Experimental eye research,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
December 1999,
The Journal of experimental medicine,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
August 1988,
The Journal of clinical investigation,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
July 1993,
Immunology,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
January 1992,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
March 1994,
European journal of immunology,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
March 1987,
The Journal of biological chemistry,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
February 1995,
Digestive diseases and sciences,
P L Kilian, and
K L Kaffka, and
A S Stern, and
D Woehle, and
W R Benjamin, and
T M Dechiara, and
U Gubler, and
J J Farrar, and
S B Mizel, and
P T Lomedico
January 1987,
Rheumatology international,
